Pacira (PCRX) BioSciences reported it has received a Paragraph IV Certification Notice Letter from Qilu Pharmaceutical, a private Chinese company. Qilu has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a generic equivalent of EXPAREL.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: